More on MRK
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $147.15 |
|
|||
| Open | $147.08 | ||||
| 52 Wk High | $65.46 | ||||
| 52 Wk Low | $47.97 | ||||
| Day High | $147.84 | ||||
| Day Low | $145.74 | ||||
| P/E | 99.91 | ||||
| EPS | $1.47 | ||||
| Volume | 31,159,364 | ||||
- EU panel backs Merck's Keytruda plus Padcev for bladder cancer
- Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIB
- Merck Launches Your Hive of Whole Health to Support Whole Person Care for People Living With HIV
- Perspective Therapeutics and Merck to test cancer drug combination
- Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors
- Merck (MRK) PT Raised to $137 at Berenberg
- Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
- Merck (MRK) PT Raised to $172 at HSBC
- FDA set to permanently fill top drug, vaccine, and tobacco roles - Bloomberg
- Merck (MRK) PT Raised to $170 at Guggenheim
Entities mentioned with MRK
- Twitter | View Related Stories »
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Earnings | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- PDUFA | View Related Stories »
- Show More...
